CYP2C19基因型与冠心病精准抗血小板治疗
网络出版日期: 2022-07-26
基金资助
国家重点研发计划精准医学研究重点专项(2017YFC0908800)
刘晓丽, 马晓腾 . CYP2C19基因型与冠心病精准抗血小板治疗[J]. 内科理论与实践, 2021 , 16(03) : 161 -166 . DOI: 10.16138/j.1673-6087.2021.03.005
| [1] | Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2019, 12(16): 1521-1537. |
| [2] | Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009, 360(4): 354-362. |
| [3] | Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11): 1045-1057. |
| [4] | Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2007, 357(20): 2001-2015. |
| [5] | Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology[J]. Eur Heart J, 2011, 32(15): 1854-1864. |
| [6] | Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J]. Lancet, 2010, 376(9749): 1320-1328. |
| [7] | Cavallari LH, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy[J]. Pharmgenomics Pers Med, 2011, 4: 123-136. |
| [8] | Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. Nat Rev Cardiol, 2014, 11(10): 597-606. |
| [9] | Xi Z, Fang F, Wang J, et al. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations[J]. Platelets, 2019, 30(2): 229-240. |
| [10] | Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update[J]. Clin Pharmacol Ther, 2013, 94(3): 317-323. |
| [11] | Cao Y, Li L, Xu M, et al. The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals[J]. Cell Res, 2020, 30(9): 717-731. |
| [12] | Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis[J]. JAMA, 2010, 304(16): 1821-1830. |
| [13] | Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis[J]. Circ Cardiovasc Genet, 2014, 7(6): 895-902. |
| [14] | Biswas M, Kali SK. Association of CYP2C19 loss-of-function alleles with major adverse cardiovascular events of clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention: meta-analysis[J]. Cardiovasc Drugs Ther, 2021. [Epub ahead of print]. |
| [15] | Zhang L, Yang J, Zhu X, et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention-a systematic review and meta-analysis[J]. Thromb Res, 2015, 135(3): 449-458. |
| [16] | Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation, 2010, 121(4): 512-518. |
| [17] | Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. J Thromb Haemost, 2012, 10(2): 199-206. |
| [18] | Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events[J]. Am Heart J, 2010, 160(3): 506-512. |
| [19] | Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response[J]. J Thromb Haemost, 2013, 11(9): 1640-1646. |
| [20] | Lewis JP, Backman JD, Reny JL, et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients[J]. Eur Heart J Cardiovasc Pharmacother, 2020, 6(4): 203-210. |
| [21] | Lee CR, Thomas CD, Beitelshees AL, et al. Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention[J]. Clin Pharmacol Ther, 2021, 109(3): 705-715. |
| [22] | Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2010, 56(4): 321-341. |
| [23] | Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention[J]. Circulation, 2011, 124(23): e574-e651. |
| [24] | Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease[J]. J Am Coll Cardiol, 2016, 68(10): 1082-1115. |
| [25] | Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS[J]. Eur J Cardiothorac Surg, 2018, 53(1): 34-78. |
| [26] | Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3): 407-477. |
| [27] | Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14): 1289-1367. |
| [28] | Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2018, 71(17): 1869-1877. |
| [29] | Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI[J]. N Engl J Med, 2019, 381(17): 1621-1631. |
| [30] | Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention[J]. JAMA, 2020, 324(8): 761-771. |
/
| 〈 |
|
〉 |
